Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
David J. Sullivan, Massimo Franchini, Jonathon W. Senefeld, et al.
Journal of General Virology (2023) Vol. 104, Iss. 5
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
Daniele Focosi, Rodrigo Quiroga, Scott A. McConnell, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2264-2264
Open Access | Times Cited: 114
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M. Bloch, Daniele Focosi, Shmuel Shoham, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 11, pp. 2018-2024
Open Access | Times Cited: 35
SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
Arturo Casadevall, Daniele Focosi
Journal of Clinical Investigation (2023) Vol. 133, Iss. 6
Open Access | Times Cited: 31
SARS‐CoV‐2 IgG antibodies in COVID‐19 convalescent plasma and conventional plasma units
Andrew Sulaiman, Isabella Sengsouk, Jodie L. White, et al.
Transfusion (2025)
Closed Access
SARS‐COV‐2 Omicron subvariant BF.7 is again triggering the Covid fear: What we need to know and what we should do?
Adnan Akif, Mohiuddin Ahmed Bhuiyan, Md. Rabiul Islam
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 19
Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies
Ranjit Sah, Mohammed Amir Rais, Aroop Mohanty, et al.
International Journal of Surgery Open (2023) Vol. 55, pp. 100625-100625
Open Access | Times Cited: 17
Antiviral combination therapies for persistent COVID-19 in immunocompromised patients
Daniele Focosi, Fabrizio Maggi, Alessandra D’Abramo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 55-59
Open Access | Times Cited: 16
Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review
Santenna Chenchula, Krishna Chaitanya Amerneni, Mohan Krishna Ghanta, et al.
Virology (2023) Vol. 584, pp. 38-43
Open Access | Times Cited: 15
Genomic surveillance of SARS-CoV-2 positive passengers on flights from China to Italy, December 2022
Federica Novazzi, Emanuela Giombini, Martina Rueca, et al.
Eurosurveillance (2023) Vol. 28, Iss. 2
Open Access | Times Cited: 13
SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Vaccines (2023) Vol. 11, Iss. 11, pp. 1634-1634
Open Access | Times Cited: 13
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Han-Sol Park, Anna Yin, Caelan Barranta, et al.
JCI Insight (2024) Vol. 9, Iss. 8
Open Access | Times Cited: 3
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Massimo Franchini, Arturo Casadevall, Michael J. Joyner, et al.
Life (2023) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 8
Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID‐19
Tsofia Inbar, Eldad J. Dann, Omer Kerner, et al.
Transfusion (2024) Vol. 64, Iss. 3, pp. 443-448
Closed Access | Times Cited: 2
The re-emergence of COVID-19 in China is a big threat for the world: Associated risk factors and preventive measures
Sampa Barai, Mohammad Fahim Kadir, Mohammad Shahriar, et al.
Annals of Medicine and Surgery (2023) Vol. 85, Iss. 2, pp. 348-350
Open Access | Times Cited: 6
The value of observational registry studies for the next infectious disease emergency
Jonathon W. Senefeld, Peter Marks, Arturo Casadevall, et al.
mBio (2023) Vol. 14, Iss. 6
Open Access | Times Cited: 5
Effect of SARS-CoV-2 IgG Seroconversion After Convalescent Plasma Transfusion on Hospital Outcomes in COVID-19
Sonal Pannu, Michael H. Cardone, Mohankumar Doraiswamy, et al.
CHEST Critical Care (2024) Vol. 2, Iss. 2, pp. 100048-100048
Open Access | Times Cited: 1
Convalescent Plasma and Other Antibody Therapies for Infectious Diseases—Lessons Learned from COVID-19 and Future Prospects
David J. Sullivan
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Convalescent Plasma Versus Hyperimmune Immunoglobulins
Daniele Focosi, Massimo Franchini, Emanuele Nicastri, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 9, pp. 1356-1357
Closed Access | Times Cited: 3
A Simple Epidemiologic Model for Predicting Impaired Neutralization of New SARS-CoV-2 Variants
Giuseppe Lippi, Brandon Michael Henry, Mario Plebani
Vaccines (2023) Vol. 11, Iss. 1, pp. 128-128
Open Access | Times Cited: 2
Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Replacement Therapy for Immunocompromised Patients
Jonathon W. Senefeld, Michael J. Joyner
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 961-963
Closed Access | Times Cited: 2
Is convalescent plasma still useful as a covid treatment?
Katharine Lang
BMJ (2023), pp. p2185-p2185
Open Access | Times Cited: 2
Hundred-fold increase in SARS-CoV-2 spike antibody levels over three years in a hospital clinical laboratory
Patrizio Caturegli, Oliver Laeyendecker, Aaron A.R. Tobian, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 2
Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
Daniele Focosi, Massimo Franchini, Jonathon W. Senefeld, et al.
Journal of Clinical Virology Plus (2022) Vol. 3, Iss. 1, pp. 100128-100128
Open Access | Times Cited: 4
Towards the identification of the correct place for convalescent plasma among COVID-19 therapies
Massimo Franchini, Daniele Focosi
Infectious Diseases (2024) Vol. 56, Iss. 6, pp. 421-422
Open Access
Time‐series transcriptome analysis of peripheral blood mononuclear cells obtained from individuals who received the SARS‐CoV‐2 mRNA vaccine
Yoshiyuki Watanabe, Hiroyuki Yamamoto, Ikuro Matsuba, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top